Patents Represented by Attorney Michael P. Morris
  • Patent number: 8242140
    Abstract: Compounds of formula I: wherein X, R2, R3, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.
    Type: Grant
    Filed: July 31, 2008
    Date of Patent: August 14, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Pierre L. Beaulieu, Paul J. Edwards, Martin Poirier, Jean Rancourt, Timothy A. Stammers
  • Patent number: 8232293
    Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: July 31, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thilo Berkenbusch, Carl Alan Busacca, Burkhard Jaeger, Richard J. Varsolona
  • Patent number: 8232286
    Abstract: New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: July 31, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steffen Breitfelder, Udo Maier, Trixi Brandl, Christoph Hoenke, Matthias Grauert, Alexander Pautsch, Matthias Hoffmann, Frank Kalkbrenner, Anne T. Joergensen, Gerhard Schaenze, Stefan Peters, Frank Buettner, Eckhart Bauer
  • Patent number: 8232312
    Abstract: The present invention relates to substituted arylsulphonylglycines of general formula (I) wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof, which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as pharmaceutical compositions.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: July 31, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Holger Wagner, Elke Langkopf, Matthias Eckhardt, Ruediger Streicher, Corinna Schoelch, Annette Schuler-Metz, Alexander Pautsch
  • Patent number: 8232281
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: July 31, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
  • Patent number: 8226982
    Abstract: The invention therefore relates to protein-containing powders, wherein the proportion of phenylalanine is at least 30% (w/w), or at least 40% (w/w). It has been shown that phenylalanine-containing powders, particularly after spray drying, are very suitable in terms of their aerodynamic characteristics and protein stabilization for preparing powders or protein compositions with improved aerodynamic properties. The main component is phenylalanine and the optional further component is an excipient which has good water-solubility compared with phenylalanine, preferably a sugar or a polyol.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: July 24, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Torsten Schultz-Fademrecht, Patrick Garidel, Beate Fischer, Karoline Bechtold-Peters
  • Patent number: 8222402
    Abstract: A process for preparing compounds of the formula (I) in which R1.1, R1.2, R1.3 and R2 are as defined in the description.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: July 17, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kathrin Pachur, Stefan Goepper, Guenther Huchler, Michael Konrad, Kathrin Maier, Werner Rall, Uwe Joerg Ries, Andreas Zopf
  • Patent number: 8222264
    Abstract: The present invention relates to substituted amino-quinazolinones of general formula (I) wherein the groups R1 to R14 and A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: July 17, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Fuchs, Niklas Heine, Christian Eickmeier, Sandra Handschuh, Cornelia Dorner-Ciossek, Stefan Hoerer
  • Patent number: 8222369
    Abstract: Disclosed is a process for preparing a macrocyclic compound of the formula (I) wherein a hydroxyl-substituted macrocyclic compound of formula (3) is reacted with a sulfonyl-substituted compound of formula QUIN: The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: July 17, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Fabrice Gallou, Nizar Haddad, Azad Hossain, Suresh R. Kapadia, Jianxiu Liu, Chris H. Senanayake, Xudong Wei, Nathan K. Yee
  • Patent number: 8221999
    Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: July 17, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Hitto Kaufmann, Lore Florin, Eric Becker, Monilola Olayioye, Angelika Hausser, Tim Fugmann
  • Patent number: 8211923
    Abstract: The present invention relates to substituted arylsulphonylaminomethyl-phosphonic acid derivatives of general formula wherein R, X, Y and Z are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and salts thereof which have valuable pharmacological properties, particularly the suppression of the interaction of glycogen phosphorylase a with the GL subunit of glycogen-associated protein phosphatase 1 (PP1), and their use as pharmaceutical compositions.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: July 3, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Holger Wagner, Elke Langkopf, Matthias Eckhardt, Ruediger Streicher, Corinna Schoelch, Annette Schuler-Metz, Alexander Pautsch
  • Patent number: 8212040
    Abstract: Compounds of Formula (IA) wherein R1, R2, R3, R4 and R5 are as defined herein for Formula (IA), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: July 3, 2012
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Younes Bekkali, Rajashehar Betageri, Mario G. Cardozo, Thomas A. Gilmore, Christian Hanke Justus Joachim Harcken, Thomas Martin Kirrane, Daniel Kuzmich, John Robert Proudfoot, Doris Riether, Hidenori Takahashi, David S. Thomson, Ji Wang, Renee M. Zindell, Hossein Razavi
  • Patent number: 8212049
    Abstract: Disclosed is a new class of chiral bidentate ligands capable of performing asymmetric hydrogenation. Also disclosed are processes of performing asymmetric hydrogenation the chiral bidentate ligands.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: July 3, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Jon Charles Lorenz
  • Patent number: 8207179
    Abstract: The present invention encompasses compounds of general Formula (1) wherein R2, R3, Q, W, X, Y and Z are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Bodo Betzemeier, Guido Boehmelt, Ulrich Guertler, Thomas Karner, Oliver Kraemer, Daniel Kuhn, Jens Juergen Quant, Ulrich Reiser, Otmar Schaaf, Flavio Solca, Heinz Stadtmueller, Ulrike Tontsch-Grunt, Matthias Treu, Stephan Karl Zahn
  • Patent number: 8205613
    Abstract: A preferably pulverulent formulation to be dosed is received in a dosing chamber having a partly gas-permeable wall. The introduction and discharge of the formulation is achieved by means of a pumping device that alternately generates a negative pressure and an excess pressure in the dosing chamber. The dosing chamber can also be displaced between a receiving position and a discharge position by means of a piston, the piston controlling the negative and excess pressure in the dosing chamber. Furthermore, the size of the dosing chamber is adjustable.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Heinrich Kladders
  • Patent number: 8207349
    Abstract: The present invention encompasses compounds of the general formula (1) in which R1 to R3 are defined as in claim 1, which are suitable for treating diseases which are characterized by excessive or anomalous cell proliferation, and their use for producing a pharmaceutical having the abovementioned properties.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bodo Betzemeier, Trixi Brandl, Steffen Breitfelder, Ralph Brueckner, Thomas Gerstberger, Michael Gmachl, Matthias Grauert, Frank Hilberg, Christoph Hoenke, Matthias Hoffmann, Maria Impagnatiello, Dirk Kessler, Christian Klein, Bernd Krist, Udo Maier, Darryl McConnell, Charlotte Reither, Stefan Scheuerer, Andreas Schoop, Norbert Schweifer, Oliver Simon, Martin Steegmaier, Steffen Steurer, Irene Waizenegger, Ulrike Weyer-Czernilofsky, Andreas Zoephel
  • Patent number: 8207335
    Abstract: The present invention relates to a method of preparing compounds of general formula I wherein m, n, R1 and R2 are defined as mentioned hereinafter, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Adil Duran, Markus Frank, Waldemar Pfrengle, Juergen Schnaubelt
  • Patent number: 8202867
    Abstract: Disclosed are hydrates and polymorphs of 4- [[(7R)-8-cyclopentyl-7 -ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide: as well as, processes for preparing them and their use as pharmaceutical compositions with antiproliferative activity.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: June 19, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Guenter Linz, Peter Sieger, Gerd F. Kraemer, Matthias Hoffmann
  • Patent number: 8202967
    Abstract: The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: June 19, 2012
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Eric Vaughn, Paulino Carlos Gonzalez-Hernandez, Juergen Däemmgen
  • Patent number: 8203001
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, M1, L1 and Q are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: June 19, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ulrich Reiser, Peter Ettmayer, Oliver Kraemer, Peter Sennhenn, Walter Spevak